

**Freedom of Information Act 2000 - Request Reference FoI/23/259**  
**Anti-VEGF Treatments**

**Information Requested:**

1. For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition:

Drugs	Jan-23	Feb-23	Mar-23	Apr-23
Aflibercept-Eylea	576	614	662	542
Ranibizumab - Lucentis	102	20	31	20
Ranibizumab - Ongavia	147	201	198	172
Dexamethasone-Ozurdex	10	18	14	8

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Drugs	Jan-23	Feb-23	Mar-23	Apr-23
Aflibercept-Eylea	17	20	27	14
Ranibizumab - Lucentis	0	0	0	0
Ranibizumab - Ongavia	0	3	4	12
Dexamethasone-Ozurdex	0	0	0	0